SlideShare una empresa de Scribd logo
1 de 116
Descargar para leer sin conexión
Perjeta
Perjeta
PERJETA® is a first-line treatment for HER2positive metastatic breast cancer.
• PERJETA is an FDA-approved
treatment for HER2-positive
metastatic breast cancer. It is
a targeted therapy used as
part of a first-line HER2positive metastatic breast
cancer treatment plan, in
combination with Herceptin
(trastuzumab) and docetaxel
(chemotherapy).
PERJETA is referred to as a HER2
dimerization inhibitor (HDI).
PERJETA is referred to as a HER2
dimerization inhibitor (HDI).
• Learn more about HDIs.
HER family receptors are activated by ligand-induced
dimerization, or receptor pairing.3 Dimerization is a critical
step in HER family-mediated signaling, and HER receptors
are able to homodimerize or heterodimerize with
Perjeta
What is HER2-positive breast cancer?
All cells have HER2 receptors, including healthy cells and cancer cells. In
HER2-positive breast cancer, tumor cells have more HER2 receptors than
normal. Too much HER2 makes these cancer cells grow and divide too
rapidly.
NONCANCEROUS CELL
What is HER2-positive breast cancer?
All cells have HER2 receptors, including healthy cells and cancer cells. In HER2-positive breast
cancer, tumor cells have more HER2 receptors than normal. Too much HER2 makes these
cancer cells grow and divide too rapidly.
HER2-POSITIVE CANCER CELL

Cancer treatments called HER2-targeted therapies have been
developed to target the HER2 receptor.
PERJETA is one of those HER2-targeted therapies.
PERJETA is a targeted therapy for treating HER2-positive metastatic breast cancer.

PERJETA was designed to search
for and attack cancer cells with
too much HER2
HER2 tells cancer cells to grow by
sending signals
HER2 works by sending signals
that tell cells to grow and divide
One way that HER2 can send
signals is by pairing with other
HER receptors. This process is
called dimerization
PERJETA is a targeted therapy for treating HER2-positive metastatic breast cancer.

PERJETA works with Herceptin to target
HER2
PERJETA and Herceptin both target HER2
but work in different ways
PERJETA is thought to block one method
of signaling so that certain receptors are
unable to pair (dimerization) with HER2
Together, PERJETA and Herceptin are
thought to create a stronger blockade
against HER2 signals, helping to slow
down cancer cell growth

HER2 signaling could inhibit the growth of tumors.
Perjeta
PERJETA is proven to help control cancer growth
Adding PERJETA to Herceptin and docetaxel (chemotherapy) increased the time people
lived without their cancer growing or spreading by an average of 50%, compared with
people who took Herceptin and docetaxel (chemotherapy) alone
ERJETA helped people live longer
On average, people who were given PERJETA, Herceptin, and docetaxel
(chemotherapy) lived significantly longer than people given only Herceptin and
docetaxel (chemotherapy)

PERJETA is proven to shrink tumors
80% of people taking the PERJETA combination had their tumors shrink, compared to
69% of people taking Herceptin and docetaxel (chemotherapy) alonePeople who had
their tumors shrink maintained this response, on average, for 62% longer on the
PERJETA combination compared with people taking only Herceptin and docetaxel
(chemotherapy) (20.2 months vs 12.5 months)
PERJETA is taken together with Herceptin, another HER2 therapy
PERJETA is a targeted therapy used as part of a first-line HER2-positive metastatic
breast cancer treatment plan. This treatment plan includes Herceptin and docetaxel, a
type of chemotherapy. PERJETA and Herceptin both target HER2 but are believed to
work in complementary ways. The combination may increase death of cancer cells.
THE BREAST
I. Introduction/General Information

A. Embryologically: belong to integument
B. Functionally: part of reproductive
system
1. Respond to sexual stimulation

2. Feed babies
Breast, continued …

C. Modified apocrine sweat glands
- apex of cell becomes part of secretion
and breaks off
D. Present in males and females
II. Anatomy
A. Position and Attachment
1. Lateral aspect of pectoral region
2.
3.
4.
5.

Located between ribs 3 and 6/7
Extend form sternum to axilla
Surrounded by superficial fascia
Rest on deep fascia
Breast Anatomy
Position & attachment, continued ….

6. Fixed to skin & underlying
fascia by fibrous C.T. bands
a. Cooper’s (Suspensory)
Ligaments
b. Ligaments may retract when
breast tumors are present
Cooper’s Suspensory Ligaments
Position & attachment, continued …

6. Left breast is usually slightly larger
7. Base is circular, either flattened or
concave
8. Separated from pectoralis major
muscle by fascia, retromammary

space
Retromammary Space

Retromammary
Space
Anatomy, continued …
B. Structure
1. Outer surface convex, skin covered
2. Nipple:
a. At fourth intercostal space
b. Small conical/cylindrical
prominence below center
Nipple location

4th intercostal
space
Structure, continued …
c. Surrounded by areola: pigmented
ring of skin
d. Thin skinned region lacking hair,
sweat glands
e. Contains areolar glands
Structure, continued …
3. Areola: contains dark pigment that
intensifies with pregnancy
a. Circular and radial smooth muscle fibers
b. Cause nipple erection
Areola
Structure, continued …

4. Each breast consists of ~ 20 lobes
of secretory tissue
a. Each lobe has one lactiferous duct
b. Lobes (and ducts) arranged radially
c. Embedded in connective tissue &
adipose of superficial fascia
d. Lobes composed of lobules
e. Lobules comprise alveoli
Lobes and Lobules
Structure, continued …
5. Excretory (lactiferous) ducts
converge toward areola
a. Form ampullae (collection sites of
lactiferous sinuses)

b. Ducts become contracted at base of
nipple
Excretory (lactiferous) ducts
Structure, continued …

6. Secretory epithelium
a. Changes with hormonal signals
b. Onset of menstruation
c. Pregnancy (glands begin to enlarge at 2nd month)
d. After birth, 1st secretion is colostrom (contain
antibodies)
Structure, continued …

7. “Tail of Spence” = axillary tail
a. prolongation of upper, outer
quadrant in axillary direction
b. Passes under axillary fascia
c. May be mistaken for axillary lymph
nodes
“Tail of Spence”
Axillary Tail
Structure, continued …

8. Fatty Tissue: surrounds surface, fills
spaces between lobes
a. Determines form & size of breast
b. No fatty deposit under nipple &
areola
Breast: Fatty Tissue
Structure, continued …
C. Vessels & nerves
1. Arteries: derived from thoracic
branches of three pairs of arteries
a. Axillary arteries

1) continuous with subclavian a.
2) gives rise to external mammary
( = lateral thoracic) artery
Vessels & Nerves, continued …
b. Internal mammary (thoracic) arteries

1) first descending branch of
subclavian artery
2) supply intercostal spaces & breast
3) used for coronary bypass surgery

c. Intercostal arteries:
1) numerous branches from internal
& external mammary arteries
2) supply intercostal spaces & breast
Arterial Supply to the Breast

Subclavian a.

Axillary a.

External
mammary
(thoracic) a.

Internal
mammary
(thoracic) a.
Vessels & Nerves, continued …
2. Veins:
a. form a ring around the base of the
venosus”)

nipple (“circulus

b. Large veins pass from circulus venosus to circumference of
mammary gland, then to
c. External mammary v to axillary v
or
d. Internal mammary v to subclavian v
Veins draining the Breast

Subclavian vein

External
mammary vein
Breast Anatomy, con’t…
3. Innervation: derived from:
a. anterior & lateral cutaneous
nerves of thorax
b. spinal segments T3 – T6
Structure, continued …

4. Lymphatics: clinically significant!
a. Glandular lymphatics drain into anterior axillary (pectoral)
nodes 
central axillary nodes  apical nodes 
deep cervical nodes 
subclavicular (subclavian) nodes

b. Medial quadrants drain into parasternal nodes
Lymph Nodes of the Breast

Subclavian
nodes
Axillary
nodes
Lateral
pectoral
nodes

Parasternal
nodes
Lymphatics, continued …
c. Superficial regions of skin, areola, nipples:
-form large channels & drain into pectoral nodes

d. NOTE: axillary nodes also drain lymph from arm
Lymph Nodes and Lymph Drainage

Axillary
Nodes
Routes of Metastasis
• From medial lymphatics to parasternal nodes
– Then to mediastinal nodes

• Across the sternum in lymphatics to
opposite side via cross-mammary pathways
– Then to contralateral breast

• From subdiaphragmatic lymphatics to nodes in
abdomen
– Then to liver, ovaries, peritoneum
Major Routes of Metastasis

Channels to Contralateral Breast

Axillary Lymph Channels

Subdiaphragmatic Lymph Channels
Structure, continued …
D. Anomalies
1. Inverted nipple: congenital or due
to cancer
2. Ectopic nipple:
a. “polythelia” or “hyperthelia”
b. additional nipples along milk line

3. Amastia
4. Micromastia
Anomalies, continued …
5. Macromastia
6. Gynecomastia
a. breast development of male in areolar region
b. noted in males who smoke marijuana at
puberty
III. Diseases of the Breast
A. Most are readily detectable
B. Etiology unknown, influencing factors

1. Sex
2. Heredity
Diseases of the breast, continued …
3. Endocrine influence
a. Menstruation – tenderness from fluid engorgement
b. Post-menopause
1) decrease of fibro-cystic disease
2) increase in cancer
c. Pregnancy
Diseases of the Breast, continued …

C. General symptoms & signs
1. Nipple discharge
a. always significant if not pregnant.

b. May be due to benign pituitary tumor.

2. Local pain, tenderness
3. Duration of lesion
4. Size, rate of growth
Symptoms & Signs, continued …

5. Retraction sign: “dimpling” involving
skin, nipple or areola
6. Mobility of mass
a. Benign = movable
1) not attached
2) not invasive
b. Malignant = attached
1)May grow into bone
Symptoms & Signs, continued …
7. Consistency of mass
a. Cysts = fluctuant; compressible
b. Fibroadenoma = rubbery
c. Carcinoma = firm, hard (like gravel)

8. Axillary area lymph node enlargement
D. Benign breast conditions
1. Infection = usually during or after
lactation
a. Recurrent, subareolar abscess
b. TB of the breast

2. Trauma = contusion
3. Hypertrophy = seen in either sex at adolescence
a. Gynecomastia = in males
Hypertrophy, continued …
b.

Other causes
1) testicular or pituitary tumor
2) cirrhosis
3) hypogonadism = not enough testosterone
4) estrogen administration for prostate cancer
Breast Cancer
Breast cancer originates in breast
tissue and arises from the ductal
tissue of the breast and, less
commonly, the lobulartissue. There
are several forms of breast cancer
based, in part, on cellular and
genetic characteristics,
Types of Breast Cancer
HER2-Positive
Overabundance of the HER2 protein
classifies the breast cancer as HER2positive and causes breast cancer
cells to multiply, spread more rapidly,
and survive longer than other
breast cancers
Ductal Carcinoma in situ (DCIS)

Ductal
cancer
cells

Carcinoma refers to any
cancer that begins in the
skin or other tissues that
cover internal organs
63
Illustration © Mary K. Bryson

Normal
ductal
cell
Hormone Receptor-Positive
Breast cancer cells that express
hormone receptors for estrogen
(ER) and/or progesterone (PR)
are dependent on the signaling
of those receptors
Invasive Ductal Carcinoma (IDC –
80% of breast cancer)

Ductal cancer cells
breaking through
the wall

• The cancer has spread to the
surrounding tissues
65
Illustration © Mary K. Bryson
Perjeta
67

Illustration © Mary K. Bryson

Range of
Ductal Carcinoma in situ
Invasive Lobular Carcinoma (ILC)

Lobular cancer
cells breaking
through the wall
68
Illustration © Mary K. Bryson
Cancer Can also Invade Lymph or
Blood Vessels

Cancer cells
invade
lymph duct
Cancer cells
invade
blood vessel
69

Illustration © Mary K. Bryson
Perjeta
Perjeta
Mammography
• Use a low-dose x-ray system to examine
breasts
• Digital mammography replaces x-ray
film by solid-state detectors that
convert x-rays into electrical signals.
These signals are used to produce images
that can be displayed on a computer
screen (similar to digital cameras)
• Mammography can show changes in the
breast up to two years before a
physician can feel them
72
Computer-Aided Diagnosis
• Mammography allows for efficient
diagnosis of breast cancers at an
earlier stage
• Radiologists misdiagnose 10-30%
of the malignant cases
• Of the cases sent for surgical
biopsy, only 10-20% are
actually malignant

CAD systems
can assist
radiologists to
Reduce these
problems

National Cancer Institute

73
What Mammograms Show
Two of the most important mammographic
indicators of breat cancers
– Masses

– Microcalcifications: Tiny flecks of calcium – like
grains of salt – in the soft tissue of the breast
that can sometimes indicate an early cancer.

74
Detection of Malignant Masses
Malignant masses have a more spiculated
appearance
benign
malignant

75
Mammogram – Difficult Case
• Heterogeneously dense breast
• Cancer can be difficult to
detect with this type of
breast tissue

• The fibroglandular tissue
(white areas) may hide the
tumor
• The breasts of younger
women contain more glands
and ligaments resulting in
dense breast tissue
76
Mammogram – Easier Case
• With age, breast tissue
becomes fattier and has
fewer glands
• Cancer is relatively easy
to detect in this type of
breast tissue

77
Different Views
Side-to-Side

MRI - Cancer can have a unique
appearance – many small irregular
white areas that turned out to be
cancer (used for diagnosis)

Top-to-Bottom

78
Perjeta
Benign Conditions, continued

4. Tumors & cysts
a. Fibroadenoma =
most common
benign breast
tumor
Tumors and Cysts, con’t…
b. Breast Cyst
1. Benign
2. May be aspirated
if large
Benign conditions, continued …
c. Fibrocystic breast
changes
1) 20%+ of remenopausal
women
2) discomfort, cysts
3) treatment rarely
required
4) More likely to not
detect a developing
cancer
Tumors & cysts, continued ….
d. Intraductal papilloma
- may produce “chocolate”
or
bloody
discharge from nipple
e. Lipoma: common
- fatty tumors
Carcinoma of the breast
1.

Most common malignant tumor among
women

2. 1/8 of women will develop breast cancer

a. 1/6 in Orange County
b. 1/5 in San Francisco
3. Generally no discomfort
Progression to Breast Cancer
Carcinoma of breast, continued …
4.

Physical signs:
a.
b.
c.
d.
e.

Slowly growing, painless mass
May demonstrate retracted nipple
May be bleeding from nipple
May be distorted areola, or breast contour
Skin dimpling in more advanced stages with
retraction of Cooper’s ligaments
Physical signs, continued …
f. Attachment of mass
g. Edema of skin
1)with “orange skin” appearance (peau d’orange)

2) due to blocked lymphatics

h. Enlarged axillary or deep cervical lymph nodes
Breast Cancer, con’t…
5. Common sites for metastasis
a. Lungs & pleura
b. Skeleton system (skull, vertebral column,
pelvis)
c. Liver

6. Atypical carcinomas
a. Inflammatory carcinoma (hormonal,
chemotherapy)
b. Paget’s disease of the breast

pagget's
disease
Scalar Field
• A scalar field is a n-dimensional space
with a scalar value attached to each
point in the space (e.g., a gray-scale
image)

89
Scalar Field and Gradient
• A scalar field is a n-dimensional space
with a scalar value attached to each
point in the space (e.g., a gray-scale
image)
• The derivative of a scalar field results
in a vector field called the gradient
– i.e., the gradient is a vector field
• which points in the direction of the greatest
rate of increase of the scalar field, and
• whose magnitude is the greatest rate of change
90

Black representing
Higher values
Gradient
The derivative of a scalar field
results in a vector field called
the gradient
– i.e., the gradient is a vector
field
• which points in the direction of
the greatest rate of increase
of the scalar field, and
• whose magnitude is the
greatest rate of change
91

Black representing
Higher values
Cartesian Gradient

g (P )

For an image function
I(P) where P is a pixel,
the Cartesian gradient
at P is:
I ( P)

92

I ( P)
y

I ( P)
x

tan

Magnitude:

Orientation:
arctan

P

x
I ( P)
y

g ( P)

( P)

(P)

I ( P)
y
I ( P)
x

m( P)

I ( P)
x

2

I ( P)
y

2

I ( P)
y
I ( P)
x
Radial Gradient
• The radial gradient
vector has the same
magnitude as the
Cartesian gradient
vector, but
• the orientation is given
as:

r ( P)
93

( P)

( P)

Radial gradient

r(P)


g (P )
(P)

P
(P)
Feature: Spiculation

[Huo et al.]

• Extract the mass using a
region-growing technique
• The maximum gradient and
its angle relative to the
radial direction are
computed
• Calculate the full-width at
half-maximum (FWHM)
from the cumulative
gradient orientation
histogram
94
Feature: Spiculation [Chan et al.]
• Determine the outline of
the segmented mass
• Obtain the rubber-bandstraightening-transformed
image
– The spicules become
approximately aligned in a
similar direction

• The rectangular region can
then be subjected to
texture analysis
95
Breast Calcifications
• Calcifications show up as
white spots on a mammogram
• Round well-defined, larger
calcifications (left column)
are more likely benign
• Tight cluster of tiny,
irregularly shaped
calcifications (right column)
may indicate cancer
96
Calcification Features
• The morphology of individual
calcification, e.g., shape, area,
and brightness
• The heterogeneity of
individual features
characterized by the mean,
the standard deviation, and
the maximum value for each
feature.
• Cluster features such as total
area, compactness
97
Database Approach to
Computer-Aided Diagnosis
Content-based image retrieval techniques can provide radiologists
“visual aids” to increase confidence in their diagnosis

• The database consists of a large
number of images with verified
pathology results
• Diagnosis is done by submitting
the suspected mass region as a
query to retrieve similar cases
from the database
98
A Mammography CAD System
[Giger et al.]

Probability of
malignancy
Similar images of
known diagnosis

Indicates the unknown
lesion relative to all
lesions in the database
99
Perjeta
DESCRIPTION

PERJETA® (Pertuzumab)is a recombinant humanized monoclonal
antibody that targets the extracellular dimerization domain
(Subdomain II) of the human epidermal growth factor receptor 2
protein (HER2). Pertuzumab is produced by recombinant DNA
technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic, gentamicin. Gentamicin is not detectable
in the final product. Pertuzumab has an approximate molecular
weight of 148 kDa.
PERJETA is a sterile, clear to slightly opalescent, colorless to pale
brown liquid for intravenous infusion. Each single use vial contains
420 mg of pertuzumab at a concentration of 30 mg/mL in 20 mM
L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02%
polysorbate 20.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
Mechanism of Action

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
Pharmacokinetics
PERJETA® Pertuzumab demonstrated linear
pharmacokinetics at a dose range of 2 – 25
mg/kg. Based on a population PK analysis that
included 481 patients, the median clearance
(CL) of pertuzumab was 0.24 L/day and the
median half-life was 18 days. With an initial
dose of 840 mg followed by a maintenance
dose of 420 mg every three weeks thereafter,
the steady-state concentration of pertuzumab
was reached after the first maintenance dose.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
INDICATIONS AND USAGE

1.1 Metastatic Breast Cancer (MBC)
PERJETA is indicated for use in
combination with trastuzumab and
docetaxel for the treatment of patients
with HER2-positive metastatic breast
cancer who have not received prior antiHER2 therapy or chemotherapy for
metastatic disease.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
INDICATIONS AND USAGE

1.2 Neoadjuvant Treatment of Breast Cancer
PERJETA is indicated for use in combination with
trastuzumab and docetaxel for the neoadjuvant treatment
of patients with HER2-positive, locally advanced,
inflammatory, or early stage breast cancer (either greater
than 2 cm in diameter or node positive) as part of a
complete treatment regimen for early breast cancer. This
indication is based on demonstration of an improvement
in pathological complete response rate. No data are
available demonstrating improvement in event-free
survival or overall surviva

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
DOSAGE AND ADMINISTRATION
The initial dose of PERJETA is 840 mg administered as a
60-minute intravenous infusion, followed every 3
weeks by a dose of 420 mg administered as an
intravenous infusion over 30 to 60 minutes.
When administered with PERJETA, the recommended
initial dose of trastuzumab is 8 mg/kg administered as a
90-minute intravenous infusion, followed every 3
weeks by a dose of 6 mg/kg administered as an
intravenous infusion over 30 to 90 minutes.

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
DOSAGE AND ADMINISTRATION

Metastatic Breast Cancer (MBC)
When administered with PERJETA, the
recommended initial dose of docetaxel is 75
mg/m2 administered as an intravenous infusion.
The dose may be escalated to 100 mg/m2
administered every 3 weeks if the initial dose is
well tolerated.

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
DOSAGE AND ADMINISTRATION
Neoadjuvant Treatment of Breast Cancer
PERJETA should be administered every 3 weeks for 3 to 6 cycles as part of one of the
following treatment regimens for early breast cancer [see Clinical Studies (14.2)]:

Four preoperative cycles of PERJETA in combination with trastuzumab and docetaxel
followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) as
given in Study 2

Three preoperative cycles of FEC alone followed by 3 preoperative cycles of PERJETA in
combination with docetaxel and trastuzumab as given in Study 3
 preoperative cycles of PERJETA in combination with docetaxel, carboplatin, and
Six
trastuzumab (TCH) (escalation of docetaxel above 75 mg/m2 is not recommended) as given
in Study 3
Following surgery, patients should continue to receive trastuzumab to complete 1 year of
treatment. There is insufficient evidence to recommend continued use of PERJETA for greater
than 6 cycles for early breast cancer. There is insufficient evidence to recommend
concomitant administration of an anthracycline with PERJETA, and there are no safety data
to support sequential use of doxorubicin with PERJETA.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
DOSAGE AND ADMINISTRATION

Dose Modification
For delayed or missed doses, if the time between two sequential
infusions is less than 6 weeks, the 420 mg dose of PERJETA should be
administered. Do not wait until the next planned dose. If the time
between two sequential infusions is 6 weeks or more, the initial dose of
840 mg PERJETA should be re-administered as a 60-minute intravenous
infusion followed every 3 weeks thereafter by a dose of 420 mg
administered as an intravenous infusion over 30 to 60 minutes.
PERJETA should be discontinued if trastuzumab treatment is
discontinued.
Dose reductions are not recommended for PERJETA.

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
Preparation for Administration
Administer as an intravenous infusion only. Do not administer as an
intravenous push or bolus. Do not mix PERJETA with other drugs.

Preparation
Prepare the solution for infusion, using aseptic technique, as follows:
1. Parenteral drug products should be inspected visually for particulates and
discoloration prior to administration.
2. Withdraw the appropriate volume of PERJETA solution from the vial(s).
3. Dilute into a 250 mL 0.9% sodium chloride PVC or non-PVC polyolefin
infusion bag.
4. Mix diluted solution by gentle inversion. Do not shake.
5. Administer immediately once prepared.
6. If the diluted infusion solution is not used immediately, it can be stored at
2oC to 8oC for up to 24 hours.
7. Dilute with 0.9% Sodium Chloride injection only. Do not use dextrose (5%)
solution.
PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
DOSAGE FORMS AND STRENGTHS

PERJETA (pertuzumab) 420 mg/14 mL
(30 mg/mL) in a single-use vial
CONTRAINDICATIONS
PERJETA is contraindicated in patients with known
hypersensitivity to pertuzumab or to any of its
excipients.

PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
HER2 Testing

Detection of HER2 protein overexpression is necessary for selection of patients
appropriate for PERJETA therapy because these are the only patients studied
and for whom benefit has been shown [see Indications and Usage (1) and
Clinical Studies (14)]. Patients with breast cancer were required to have
evidence of HER2 overexpression defined as 3+ IHC or FISH amplification ratio 
2.0 in the clinical studies. Only limited data were available for patients,whose
breast cancer was positive by FISH, but did not demonstrate protein
overexpression by IHC.
HER2 Testing

Assessment of HER2 status should be performed by laboratories using FDAapproved tests with demonstrated proficiency in the specific technology being
utilized. Improper assay performance, including use of sub-optimally fixed tissue,
failure to utilize specified reagents, deviation from specific assay instructions, and
failure to include appropriate controls for assay validation, can lead to unreliable
results.
ADVERSE REACTIONS
Metastatic Breast Cancer
1. The most common adverse reactions (> 30%) with PERJETA in
combination with trastuzumab and docetaxel were diarrhea, alopecia,
neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

Neoadjuvant Treatment of Breast Cancer
1. The most common adverse reactions (> 30%) with PERJETA in
combination with trastuzumab and docetaxel were alopecia, diarrhea,
nausea, and neutropenia.
2. The most common adverse reactions (>30%) with PERJETA in
combination with trastuzumab and docetaxel when given for 3 cycles
following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea,
vomiting, and neutropenia.
3. The most common adverse reactions (>30%) with PERJETA in
combination with docetaxel, carboplatin, and trastuzumab (TCH) were
fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia,
thrombocytopenia, and anemia.
Perjeta

Más contenido relacionado

La actualidad más candente

EBRT IN CARCINOMA CERVIX
EBRT IN CARCINOMA CERVIXEBRT IN CARCINOMA CERVIX
EBRT IN CARCINOMA CERVIXIsha Jaiswal
 
triple negative breast cancer
triple negative breast cancertriple negative breast cancer
triple negative breast cancerLuis Toache
 
Satyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet Rath
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinomaAnimesh Agrawal
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
Brachytherapy in Gynaecological Cancers
Brachytherapy in Gynaecological CancersBrachytherapy in Gynaecological Cancers
Brachytherapy in Gynaecological CancersPradeep Dhanasekaran
 
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCEREVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCERIsha Jaiswal
 
Radiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerRadiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerAnimesh Agrawal
 
Cervix landmark trials- kiran
Cervix landmark trials- kiran   Cervix landmark trials- kiran
Cervix landmark trials- kiran Kiran Ramakrishna
 
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPY
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPYGYNECOLOGICAL CANCER ROLE OF RADIOTHERAPY
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPYPuneet Seth
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancerManar Malik
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERAaditya Prakash
 
Hormone therapy in prostate cancer 1
Hormone therapy in prostate cancer 1Hormone therapy in prostate cancer 1
Hormone therapy in prostate cancer 1Deepika Malik
 

La actualidad más candente (20)

CA ENDOMETRIUM-KIRAN.pptx
CA ENDOMETRIUM-KIRAN.pptxCA ENDOMETRIUM-KIRAN.pptx
CA ENDOMETRIUM-KIRAN.pptx
 
EBRT IN CARCINOMA CERVIX
EBRT IN CARCINOMA CERVIXEBRT IN CARCINOMA CERVIX
EBRT IN CARCINOMA CERVIX
 
triple negative breast cancer
triple negative breast cancertriple negative breast cancer
triple negative breast cancer
 
Satyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancer
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Prostate Cancer 2013
Prostate Cancer 2013Prostate Cancer 2013
Prostate Cancer 2013
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinoma
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
Brachytherapy in Gynaecological Cancers
Brachytherapy in Gynaecological CancersBrachytherapy in Gynaecological Cancers
Brachytherapy in Gynaecological Cancers
 
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCEREVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
 
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptxMANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
 
Radiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerRadiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast Cancer
 
Cervix landmark trials- kiran
Cervix landmark trials- kiran   Cervix landmark trials- kiran
Cervix landmark trials- kiran
 
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPY
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPYGYNECOLOGICAL CANCER ROLE OF RADIOTHERAPY
GYNECOLOGICAL CANCER ROLE OF RADIOTHERAPY
 
Radiation for Cervix Cancer
Radiation for Cervix CancerRadiation for Cervix Cancer
Radiation for Cervix Cancer
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancer
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCER
 
Hormone therapy in prostate cancer 1
Hormone therapy in prostate cancer 1Hormone therapy in prostate cancer 1
Hormone therapy in prostate cancer 1
 
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptxMANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
MANAGEMENT OF EARLY OPERABLE HER2+ BREAST CANCER.pptx
 
SBRT prostate
SBRT prostate SBRT prostate
SBRT prostate
 

Destacado

Pertuzumab for HER2 Positive Metastatic Breast Cancer
Pertuzumab for HER2 Positive Metastatic Breast CancerPertuzumab for HER2 Positive Metastatic Breast Cancer
Pertuzumab for HER2 Positive Metastatic Breast CancerRod Bugawan
 
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerbreastcancerupdatecongress
 
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...European School of Oncology
 
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancerpostmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancerBharti Devnani
 
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.imrana tanvir
 
Locally Adv Breast Cancer
Locally Adv Breast CancerLocally Adv Breast Cancer
Locally Adv Breast Cancerfondas vakalis
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelinesfondas vakalis
 

Destacado (12)

Pertuzumab for HER2 Positive Metastatic Breast Cancer
Pertuzumab for HER2 Positive Metastatic Breast CancerPertuzumab for HER2 Positive Metastatic Breast Cancer
Pertuzumab for HER2 Positive Metastatic Breast Cancer
 
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
 
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...
ABC1 - F. Cardoso - HER-2+ advanced breast cancer - State-of-the-art manageme...
 
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancerpostmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
 
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in...
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in...Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in...
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in...
 
Locally advanced breast cancer
Locally advanced breast cancerLocally advanced breast cancer
Locally advanced breast cancer
 
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
 
Locally Adv Breast Cancer
Locally Adv Breast CancerLocally Adv Breast Cancer
Locally Adv Breast Cancer
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelines
 
The breast
The breastThe breast
The breast
 
What’s New With HER2?
What’s New With HER2?What’s New With HER2?
What’s New With HER2?
 
What's Hot in Breast Cancer Treatment
What's Hot in Breast Cancer TreatmentWhat's Hot in Breast Cancer Treatment
What's Hot in Breast Cancer Treatment
 

Similar a Perjeta

BREAST and carcinoma PPT.pptx
BREAST and carcinoma PPT.pptxBREAST and carcinoma PPT.pptx
BREAST and carcinoma PPT.pptxVivekP89
 
Evaluation and Management of Carcinoma Breast
Evaluation and Management of Carcinoma BreastEvaluation and Management of Carcinoma Breast
Evaluation and Management of Carcinoma BreastDavinder Pal Singh
 
1.Non-Proliferative Breast Disease. Non-Proliferative Breast
1.Non-Proliferative Breast Disease. Non-Proliferative Breast1.Non-Proliferative Breast Disease. Non-Proliferative Breast
1.Non-Proliferative Breast Disease. Non-Proliferative BreastSue Jones
 
the breast cancer and its different type ,stages and grading , the tumor mar...
 the breast cancer and its different type ,stages and grading , the tumor mar... the breast cancer and its different type ,stages and grading , the tumor mar...
the breast cancer and its different type ,stages and grading , the tumor mar...imam univarsity , college of medicine .
 
Peritoneal Asbestos Is A Uncommon Illness
Peritoneal Asbestos Is A Uncommon IllnessPeritoneal Asbestos Is A Uncommon Illness
Peritoneal Asbestos Is A Uncommon IllnessAmy Holmes
 
Anatomy and staging breast cancer
Anatomy and staging breast cancerAnatomy and staging breast cancer
Anatomy and staging breast cancerAnil Gupta
 
Breast and the Axilla
Breast and the AxillaBreast and the Axilla
Breast and the AxillaJack Frost
 
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...meducationdotnet
 

Similar a Perjeta (20)

Chapter 15
Chapter 15Chapter 15
Chapter 15
 
Breast cancer
Breast cancerBreast cancer
Breast cancer
 
BREAST and carcinoma PPT.pptx
BREAST and carcinoma PPT.pptxBREAST and carcinoma PPT.pptx
BREAST and carcinoma PPT.pptx
 
carcinoma of breast
carcinoma of breastcarcinoma of breast
carcinoma of breast
 
Evaluation and Management of Carcinoma Breast
Evaluation and Management of Carcinoma BreastEvaluation and Management of Carcinoma Breast
Evaluation and Management of Carcinoma Breast
 
Breast cancer
Breast cancerBreast cancer
Breast cancer
 
breast.pdf
breast.pdfbreast.pdf
breast.pdf
 
1.Non-Proliferative Breast Disease. Non-Proliferative Breast
1.Non-Proliferative Breast Disease. Non-Proliferative Breast1.Non-Proliferative Breast Disease. Non-Proliferative Breast
1.Non-Proliferative Breast Disease. Non-Proliferative Breast
 
the breast cancer and its different type ,stages and grading , the tumor mar...
 the breast cancer and its different type ,stages and grading , the tumor mar... the breast cancer and its different type ,stages and grading , the tumor mar...
the breast cancer and its different type ,stages and grading , the tumor mar...
 
Peritoneal Asbestos Is A Uncommon Illness
Peritoneal Asbestos Is A Uncommon IllnessPeritoneal Asbestos Is A Uncommon Illness
Peritoneal Asbestos Is A Uncommon Illness
 
Anatomy and staging breast cancer
Anatomy and staging breast cancerAnatomy and staging breast cancer
Anatomy and staging breast cancer
 
Anatomy of breast
Anatomy of breastAnatomy of breast
Anatomy of breast
 
Breastcancer 140220114523-phpapp02
Breastcancer 140220114523-phpapp02Breastcancer 140220114523-phpapp02
Breastcancer 140220114523-phpapp02
 
Breast and the Axilla
Breast and the AxillaBreast and the Axilla
Breast and the Axilla
 
Breast carcinoma
Breast carcinoma Breast carcinoma
Breast carcinoma
 
Essay On Breast Cancer
Essay On Breast CancerEssay On Breast Cancer
Essay On Breast Cancer
 
Breast cancer
Breast cancerBreast cancer
Breast cancer
 
uterus-180307171200.pdf
uterus-180307171200.pdfuterus-180307171200.pdf
uterus-180307171200.pdf
 
Gross Anatomy of Uterus
Gross Anatomy of UterusGross Anatomy of Uterus
Gross Anatomy of Uterus
 
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...
Thyroid Cancer & Differential Diagnosis of Lumps in Neck for Medical Students...
 

Más de Shimranz Skillls (20)

Tms profile
Tms profileTms profile
Tms profile
 
Gazyva
GazyvaGazyva
Gazyva
 
Listening OR HEARNG
Listening OR HEARNGListening OR HEARNG
Listening OR HEARNG
 
Why we no longer need hr departments
Why we no longer need hr departmentsWhy we no longer need hr departments
Why we no longer need hr departments
 
Designing and managing services
Designing and managing servicesDesigning and managing services
Designing and managing services
 
Attributtes of power point presentation
Attributtes of power point presentationAttributtes of power point presentation
Attributtes of power point presentation
 
Developing pricing strategies
Developing pricing strategiesDeveloping pricing strategies
Developing pricing strategies
 
The 8 attribute of great start up internship
The 8 attribute of great start up internshipThe 8 attribute of great start up internship
The 8 attribute of great start up internship
 
Disciplined team
Disciplined teamDisciplined team
Disciplined team
 
Wining
WiningWining
Wining
 
Know your-colleague
Know your-colleagueKnow your-colleague
Know your-colleague
 
Laws of-motivation
Laws of-motivationLaws of-motivation
Laws of-motivation
 
Selling skills
Selling skillsSelling skills
Selling skills
 
Design and size of sales territories
Design and size of sales territoriesDesign and size of sales territories
Design and size of sales territories
 
Sales person
Sales personSales person
Sales person
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Euglucon
EugluconEuglucon
Euglucon
 
Aab guidelines overview_06a
Aab guidelines overview_06aAab guidelines overview_06a
Aab guidelines overview_06a
 
Ulcer
UlcerUlcer
Ulcer
 
Build to last (great organization)
Build to last (great organization)Build to last (great organization)
Build to last (great organization)
 

Último

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 

Último (20)

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 

Perjeta

  • 3. PERJETA® is a first-line treatment for HER2positive metastatic breast cancer. • PERJETA is an FDA-approved treatment for HER2-positive metastatic breast cancer. It is a targeted therapy used as part of a first-line HER2positive metastatic breast cancer treatment plan, in combination with Herceptin (trastuzumab) and docetaxel (chemotherapy).
  • 4. PERJETA is referred to as a HER2 dimerization inhibitor (HDI).
  • 5. PERJETA is referred to as a HER2 dimerization inhibitor (HDI). • Learn more about HDIs.
  • 6. HER family receptors are activated by ligand-induced dimerization, or receptor pairing.3 Dimerization is a critical step in HER family-mediated signaling, and HER receptors are able to homodimerize or heterodimerize with
  • 8. What is HER2-positive breast cancer? All cells have HER2 receptors, including healthy cells and cancer cells. In HER2-positive breast cancer, tumor cells have more HER2 receptors than normal. Too much HER2 makes these cancer cells grow and divide too rapidly. NONCANCEROUS CELL
  • 9. What is HER2-positive breast cancer? All cells have HER2 receptors, including healthy cells and cancer cells. In HER2-positive breast cancer, tumor cells have more HER2 receptors than normal. Too much HER2 makes these cancer cells grow and divide too rapidly. HER2-POSITIVE CANCER CELL Cancer treatments called HER2-targeted therapies have been developed to target the HER2 receptor. PERJETA is one of those HER2-targeted therapies.
  • 10. PERJETA is a targeted therapy for treating HER2-positive metastatic breast cancer. PERJETA was designed to search for and attack cancer cells with too much HER2 HER2 tells cancer cells to grow by sending signals HER2 works by sending signals that tell cells to grow and divide One way that HER2 can send signals is by pairing with other HER receptors. This process is called dimerization
  • 11. PERJETA is a targeted therapy for treating HER2-positive metastatic breast cancer. PERJETA works with Herceptin to target HER2 PERJETA and Herceptin both target HER2 but work in different ways PERJETA is thought to block one method of signaling so that certain receptors are unable to pair (dimerization) with HER2 Together, PERJETA and Herceptin are thought to create a stronger blockade against HER2 signals, helping to slow down cancer cell growth HER2 signaling could inhibit the growth of tumors.
  • 13. PERJETA is proven to help control cancer growth Adding PERJETA to Herceptin and docetaxel (chemotherapy) increased the time people lived without their cancer growing or spreading by an average of 50%, compared with people who took Herceptin and docetaxel (chemotherapy) alone
  • 14. ERJETA helped people live longer On average, people who were given PERJETA, Herceptin, and docetaxel (chemotherapy) lived significantly longer than people given only Herceptin and docetaxel (chemotherapy) PERJETA is proven to shrink tumors 80% of people taking the PERJETA combination had their tumors shrink, compared to 69% of people taking Herceptin and docetaxel (chemotherapy) alonePeople who had their tumors shrink maintained this response, on average, for 62% longer on the PERJETA combination compared with people taking only Herceptin and docetaxel (chemotherapy) (20.2 months vs 12.5 months) PERJETA is taken together with Herceptin, another HER2 therapy PERJETA is a targeted therapy used as part of a first-line HER2-positive metastatic breast cancer treatment plan. This treatment plan includes Herceptin and docetaxel, a type of chemotherapy. PERJETA and Herceptin both target HER2 but are believed to work in complementary ways. The combination may increase death of cancer cells.
  • 16. I. Introduction/General Information A. Embryologically: belong to integument B. Functionally: part of reproductive system 1. Respond to sexual stimulation 2. Feed babies
  • 17. Breast, continued … C. Modified apocrine sweat glands - apex of cell becomes part of secretion and breaks off D. Present in males and females
  • 18. II. Anatomy A. Position and Attachment 1. Lateral aspect of pectoral region 2. 3. 4. 5. Located between ribs 3 and 6/7 Extend form sternum to axilla Surrounded by superficial fascia Rest on deep fascia
  • 20. Position & attachment, continued …. 6. Fixed to skin & underlying fascia by fibrous C.T. bands a. Cooper’s (Suspensory) Ligaments b. Ligaments may retract when breast tumors are present
  • 22. Position & attachment, continued … 6. Left breast is usually slightly larger 7. Base is circular, either flattened or concave 8. Separated from pectoralis major muscle by fascia, retromammary space
  • 24. Anatomy, continued … B. Structure 1. Outer surface convex, skin covered 2. Nipple: a. At fourth intercostal space b. Small conical/cylindrical prominence below center
  • 26. Structure, continued … c. Surrounded by areola: pigmented ring of skin d. Thin skinned region lacking hair, sweat glands e. Contains areolar glands
  • 27. Structure, continued … 3. Areola: contains dark pigment that intensifies with pregnancy a. Circular and radial smooth muscle fibers b. Cause nipple erection
  • 29. Structure, continued … 4. Each breast consists of ~ 20 lobes of secretory tissue a. Each lobe has one lactiferous duct b. Lobes (and ducts) arranged radially c. Embedded in connective tissue & adipose of superficial fascia d. Lobes composed of lobules e. Lobules comprise alveoli
  • 31. Structure, continued … 5. Excretory (lactiferous) ducts converge toward areola a. Form ampullae (collection sites of lactiferous sinuses) b. Ducts become contracted at base of nipple
  • 33. Structure, continued … 6. Secretory epithelium a. Changes with hormonal signals b. Onset of menstruation c. Pregnancy (glands begin to enlarge at 2nd month) d. After birth, 1st secretion is colostrom (contain antibodies)
  • 34. Structure, continued … 7. “Tail of Spence” = axillary tail a. prolongation of upper, outer quadrant in axillary direction b. Passes under axillary fascia c. May be mistaken for axillary lymph nodes
  • 36. Structure, continued … 8. Fatty Tissue: surrounds surface, fills spaces between lobes a. Determines form & size of breast b. No fatty deposit under nipple & areola
  • 38. Structure, continued … C. Vessels & nerves 1. Arteries: derived from thoracic branches of three pairs of arteries a. Axillary arteries 1) continuous with subclavian a. 2) gives rise to external mammary ( = lateral thoracic) artery
  • 39. Vessels & Nerves, continued … b. Internal mammary (thoracic) arteries 1) first descending branch of subclavian artery 2) supply intercostal spaces & breast 3) used for coronary bypass surgery c. Intercostal arteries: 1) numerous branches from internal & external mammary arteries 2) supply intercostal spaces & breast
  • 40. Arterial Supply to the Breast Subclavian a. Axillary a. External mammary (thoracic) a. Internal mammary (thoracic) a.
  • 41. Vessels & Nerves, continued … 2. Veins: a. form a ring around the base of the venosus”) nipple (“circulus b. Large veins pass from circulus venosus to circumference of mammary gland, then to c. External mammary v to axillary v or d. Internal mammary v to subclavian v
  • 42. Veins draining the Breast Subclavian vein External mammary vein
  • 43. Breast Anatomy, con’t… 3. Innervation: derived from: a. anterior & lateral cutaneous nerves of thorax b. spinal segments T3 – T6
  • 44. Structure, continued … 4. Lymphatics: clinically significant! a. Glandular lymphatics drain into anterior axillary (pectoral) nodes  central axillary nodes  apical nodes  deep cervical nodes  subclavicular (subclavian) nodes b. Medial quadrants drain into parasternal nodes
  • 45. Lymph Nodes of the Breast Subclavian nodes Axillary nodes Lateral pectoral nodes Parasternal nodes
  • 46. Lymphatics, continued … c. Superficial regions of skin, areola, nipples: -form large channels & drain into pectoral nodes d. NOTE: axillary nodes also drain lymph from arm
  • 47. Lymph Nodes and Lymph Drainage Axillary Nodes
  • 48. Routes of Metastasis • From medial lymphatics to parasternal nodes – Then to mediastinal nodes • Across the sternum in lymphatics to opposite side via cross-mammary pathways – Then to contralateral breast • From subdiaphragmatic lymphatics to nodes in abdomen – Then to liver, ovaries, peritoneum
  • 49. Major Routes of Metastasis Channels to Contralateral Breast Axillary Lymph Channels Subdiaphragmatic Lymph Channels
  • 50. Structure, continued … D. Anomalies 1. Inverted nipple: congenital or due to cancer 2. Ectopic nipple: a. “polythelia” or “hyperthelia” b. additional nipples along milk line 3. Amastia 4. Micromastia
  • 51. Anomalies, continued … 5. Macromastia 6. Gynecomastia a. breast development of male in areolar region b. noted in males who smoke marijuana at puberty
  • 52. III. Diseases of the Breast A. Most are readily detectable B. Etiology unknown, influencing factors 1. Sex 2. Heredity
  • 53. Diseases of the breast, continued … 3. Endocrine influence a. Menstruation – tenderness from fluid engorgement b. Post-menopause 1) decrease of fibro-cystic disease 2) increase in cancer c. Pregnancy
  • 54. Diseases of the Breast, continued … C. General symptoms & signs 1. Nipple discharge a. always significant if not pregnant. b. May be due to benign pituitary tumor. 2. Local pain, tenderness 3. Duration of lesion 4. Size, rate of growth
  • 55. Symptoms & Signs, continued … 5. Retraction sign: “dimpling” involving skin, nipple or areola 6. Mobility of mass a. Benign = movable 1) not attached 2) not invasive b. Malignant = attached 1)May grow into bone
  • 56. Symptoms & Signs, continued … 7. Consistency of mass a. Cysts = fluctuant; compressible b. Fibroadenoma = rubbery c. Carcinoma = firm, hard (like gravel) 8. Axillary area lymph node enlargement
  • 57. D. Benign breast conditions 1. Infection = usually during or after lactation a. Recurrent, subareolar abscess b. TB of the breast 2. Trauma = contusion 3. Hypertrophy = seen in either sex at adolescence a. Gynecomastia = in males
  • 58. Hypertrophy, continued … b. Other causes 1) testicular or pituitary tumor 2) cirrhosis 3) hypogonadism = not enough testosterone 4) estrogen administration for prostate cancer
  • 60. Breast cancer originates in breast tissue and arises from the ductal tissue of the breast and, less commonly, the lobulartissue. There are several forms of breast cancer based, in part, on cellular and genetic characteristics,
  • 61. Types of Breast Cancer
  • 62. HER2-Positive Overabundance of the HER2 protein classifies the breast cancer as HER2positive and causes breast cancer cells to multiply, spread more rapidly, and survive longer than other breast cancers
  • 63. Ductal Carcinoma in situ (DCIS) Ductal cancer cells Carcinoma refers to any cancer that begins in the skin or other tissues that cover internal organs 63 Illustration © Mary K. Bryson Normal ductal cell
  • 64. Hormone Receptor-Positive Breast cancer cells that express hormone receptors for estrogen (ER) and/or progesterone (PR) are dependent on the signaling of those receptors
  • 65. Invasive Ductal Carcinoma (IDC – 80% of breast cancer) Ductal cancer cells breaking through the wall • The cancer has spread to the surrounding tissues 65 Illustration © Mary K. Bryson
  • 67. 67 Illustration © Mary K. Bryson Range of Ductal Carcinoma in situ
  • 68. Invasive Lobular Carcinoma (ILC) Lobular cancer cells breaking through the wall 68 Illustration © Mary K. Bryson
  • 69. Cancer Can also Invade Lymph or Blood Vessels Cancer cells invade lymph duct Cancer cells invade blood vessel 69 Illustration © Mary K. Bryson
  • 72. Mammography • Use a low-dose x-ray system to examine breasts • Digital mammography replaces x-ray film by solid-state detectors that convert x-rays into electrical signals. These signals are used to produce images that can be displayed on a computer screen (similar to digital cameras) • Mammography can show changes in the breast up to two years before a physician can feel them 72
  • 73. Computer-Aided Diagnosis • Mammography allows for efficient diagnosis of breast cancers at an earlier stage • Radiologists misdiagnose 10-30% of the malignant cases • Of the cases sent for surgical biopsy, only 10-20% are actually malignant CAD systems can assist radiologists to Reduce these problems National Cancer Institute 73
  • 74. What Mammograms Show Two of the most important mammographic indicators of breat cancers – Masses – Microcalcifications: Tiny flecks of calcium – like grains of salt – in the soft tissue of the breast that can sometimes indicate an early cancer. 74
  • 75. Detection of Malignant Masses Malignant masses have a more spiculated appearance benign malignant 75
  • 76. Mammogram – Difficult Case • Heterogeneously dense breast • Cancer can be difficult to detect with this type of breast tissue • The fibroglandular tissue (white areas) may hide the tumor • The breasts of younger women contain more glands and ligaments resulting in dense breast tissue 76
  • 77. Mammogram – Easier Case • With age, breast tissue becomes fattier and has fewer glands • Cancer is relatively easy to detect in this type of breast tissue 77
  • 78. Different Views Side-to-Side MRI - Cancer can have a unique appearance – many small irregular white areas that turned out to be cancer (used for diagnosis) Top-to-Bottom 78
  • 80. Benign Conditions, continued 4. Tumors & cysts a. Fibroadenoma = most common benign breast tumor
  • 81. Tumors and Cysts, con’t… b. Breast Cyst 1. Benign 2. May be aspirated if large
  • 82. Benign conditions, continued … c. Fibrocystic breast changes 1) 20%+ of remenopausal women 2) discomfort, cysts 3) treatment rarely required 4) More likely to not detect a developing cancer
  • 83. Tumors & cysts, continued …. d. Intraductal papilloma - may produce “chocolate” or bloody discharge from nipple e. Lipoma: common - fatty tumors
  • 84. Carcinoma of the breast 1. Most common malignant tumor among women 2. 1/8 of women will develop breast cancer a. 1/6 in Orange County b. 1/5 in San Francisco 3. Generally no discomfort
  • 86. Carcinoma of breast, continued … 4. Physical signs: a. b. c. d. e. Slowly growing, painless mass May demonstrate retracted nipple May be bleeding from nipple May be distorted areola, or breast contour Skin dimpling in more advanced stages with retraction of Cooper’s ligaments
  • 87. Physical signs, continued … f. Attachment of mass g. Edema of skin 1)with “orange skin” appearance (peau d’orange) 2) due to blocked lymphatics h. Enlarged axillary or deep cervical lymph nodes
  • 88. Breast Cancer, con’t… 5. Common sites for metastasis a. Lungs & pleura b. Skeleton system (skull, vertebral column, pelvis) c. Liver 6. Atypical carcinomas a. Inflammatory carcinoma (hormonal, chemotherapy) b. Paget’s disease of the breast pagget's disease
  • 89. Scalar Field • A scalar field is a n-dimensional space with a scalar value attached to each point in the space (e.g., a gray-scale image) 89
  • 90. Scalar Field and Gradient • A scalar field is a n-dimensional space with a scalar value attached to each point in the space (e.g., a gray-scale image) • The derivative of a scalar field results in a vector field called the gradient – i.e., the gradient is a vector field • which points in the direction of the greatest rate of increase of the scalar field, and • whose magnitude is the greatest rate of change 90 Black representing Higher values
  • 91. Gradient The derivative of a scalar field results in a vector field called the gradient – i.e., the gradient is a vector field • which points in the direction of the greatest rate of increase of the scalar field, and • whose magnitude is the greatest rate of change 91 Black representing Higher values
  • 92. Cartesian Gradient  g (P ) For an image function I(P) where P is a pixel, the Cartesian gradient at P is: I ( P) 92 I ( P) y I ( P) x tan Magnitude: Orientation: arctan P x I ( P) y g ( P) ( P) (P) I ( P) y I ( P) x m( P) I ( P) x 2 I ( P) y 2 I ( P) y I ( P) x
  • 93. Radial Gradient • The radial gradient vector has the same magnitude as the Cartesian gradient vector, but • the orientation is given as: r ( P) 93 ( P) ( P) Radial gradient r(P)  g (P ) (P) P (P)
  • 94. Feature: Spiculation [Huo et al.] • Extract the mass using a region-growing technique • The maximum gradient and its angle relative to the radial direction are computed • Calculate the full-width at half-maximum (FWHM) from the cumulative gradient orientation histogram 94
  • 95. Feature: Spiculation [Chan et al.] • Determine the outline of the segmented mass • Obtain the rubber-bandstraightening-transformed image – The spicules become approximately aligned in a similar direction • The rectangular region can then be subjected to texture analysis 95
  • 96. Breast Calcifications • Calcifications show up as white spots on a mammogram • Round well-defined, larger calcifications (left column) are more likely benign • Tight cluster of tiny, irregularly shaped calcifications (right column) may indicate cancer 96
  • 97. Calcification Features • The morphology of individual calcification, e.g., shape, area, and brightness • The heterogeneity of individual features characterized by the mean, the standard deviation, and the maximum value for each feature. • Cluster features such as total area, compactness 97
  • 98. Database Approach to Computer-Aided Diagnosis Content-based image retrieval techniques can provide radiologists “visual aids” to increase confidence in their diagnosis • The database consists of a large number of images with verified pathology results • Diagnosis is done by submitting the suspected mass region as a query to retrieve similar cases from the database 98
  • 99. A Mammography CAD System [Giger et al.] Probability of malignancy Similar images of known diagnosis Indicates the unknown lesion relative to all lesions in the database 99
  • 101. DESCRIPTION PERJETA® (Pertuzumab)is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic, gentamicin. Gentamicin is not detectable in the final product. Pertuzumab has an approximate molecular weight of 148 kDa. PERJETA is a sterile, clear to slightly opalescent, colorless to pale brown liquid for intravenous infusion. Each single use vial contains 420 mg of pertuzumab at a concentration of 30 mg/mL in 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 102. Mechanism of Action PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 103. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 104. Pharmacokinetics PERJETA® Pertuzumab demonstrated linear pharmacokinetics at a dose range of 2 – 25 mg/kg. Based on a population PK analysis that included 481 patients, the median clearance (CL) of pertuzumab was 0.24 L/day and the median half-life was 18 days. With an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks thereafter, the steady-state concentration of pertuzumab was reached after the first maintenance dose. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 105. INDICATIONS AND USAGE 1.1 Metastatic Breast Cancer (MBC) PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 106. INDICATIONS AND USAGE 1.2 Neoadjuvant Treatment of Breast Cancer PERJETA is indicated for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall surviva PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 107. DOSAGE AND ADMINISTRATION The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes. When administered with PERJETA, the recommended initial dose of trastuzumab is 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 108. DOSAGE AND ADMINISTRATION Metastatic Breast Cancer (MBC) When administered with PERJETA, the recommended initial dose of docetaxel is 75 mg/m2 administered as an intravenous infusion. The dose may be escalated to 100 mg/m2 administered every 3 weeks if the initial dose is well tolerated. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 109. DOSAGE AND ADMINISTRATION Neoadjuvant Treatment of Breast Cancer PERJETA should be administered every 3 weeks for 3 to 6 cycles as part of one of the following treatment regimens for early breast cancer [see Clinical Studies (14.2)]:  Four preoperative cycles of PERJETA in combination with trastuzumab and docetaxel followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) as given in Study 2  Three preoperative cycles of FEC alone followed by 3 preoperative cycles of PERJETA in combination with docetaxel and trastuzumab as given in Study 3  preoperative cycles of PERJETA in combination with docetaxel, carboplatin, and Six trastuzumab (TCH) (escalation of docetaxel above 75 mg/m2 is not recommended) as given in Study 3 Following surgery, patients should continue to receive trastuzumab to complete 1 year of treatment. There is insufficient evidence to recommend continued use of PERJETA for greater than 6 cycles for early breast cancer. There is insufficient evidence to recommend concomitant administration of an anthracycline with PERJETA, and there are no safety data to support sequential use of doxorubicin with PERJETA. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 110. DOSAGE AND ADMINISTRATION Dose Modification For delayed or missed doses, if the time between two sequential infusions is less than 6 weeks, the 420 mg dose of PERJETA should be administered. Do not wait until the next planned dose. If the time between two sequential infusions is 6 weeks or more, the initial dose of 840 mg PERJETA should be re-administered as a 60-minute intravenous infusion followed every 3 weeks thereafter by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes. PERJETA should be discontinued if trastuzumab treatment is discontinued. Dose reductions are not recommended for PERJETA. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 111. Preparation for Administration Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus. Do not mix PERJETA with other drugs. Preparation Prepare the solution for infusion, using aseptic technique, as follows: 1. Parenteral drug products should be inspected visually for particulates and discoloration prior to administration. 2. Withdraw the appropriate volume of PERJETA solution from the vial(s). 3. Dilute into a 250 mL 0.9% sodium chloride PVC or non-PVC polyolefin infusion bag. 4. Mix diluted solution by gentle inversion. Do not shake. 5. Administer immediately once prepared. 6. If the diluted infusion solution is not used immediately, it can be stored at 2oC to 8oC for up to 24 hours. 7. Dilute with 0.9% Sodium Chloride injection only. Do not use dextrose (5%) solution. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 112. DOSAGE FORMS AND STRENGTHS PERJETA (pertuzumab) 420 mg/14 mL (30 mg/mL) in a single-use vial CONTRAINDICATIONS PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients. PERJETA® is a first-line treatment for HER2-positive metastatic breast cancer.
  • 113. HER2 Testing Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown [see Indications and Usage (1) and Clinical Studies (14)]. Patients with breast cancer were required to have evidence of HER2 overexpression defined as 3+ IHC or FISH amplification ratio  2.0 in the clinical studies. Only limited data were available for patients,whose breast cancer was positive by FISH, but did not demonstrate protein overexpression by IHC.
  • 114. HER2 Testing Assessment of HER2 status should be performed by laboratories using FDAapproved tests with demonstrated proficiency in the specific technology being utilized. Improper assay performance, including use of sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.
  • 115. ADVERSE REACTIONS Metastatic Breast Cancer 1. The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. Neoadjuvant Treatment of Breast Cancer 1. The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 2. The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 3. The most common adverse reactions (>30%) with PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.